1. AB0033 The identification of IL-17A+, IL-17RA+ and IL-17RC+ lymphoid and myeloid cells in blood of treatment naÏve early and in synovial fluid of established psoriatic arthritis patients. (15th June 2017) Authors: Xu, X; Davelaar, N; Otten-Mus, A-M; Asmawidjaja, PS; Braanker, H den; Alves, H; Hamburg, JP van; Gaillez, C; Hazes, JM; Bisoendial, R; Vis, M; Kolbinger, F; Lubberts, E Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1058 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0765 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved disease activity index for psoriatic arthritis (DAPSA) remission. (15th June 2017) Authors: Smolen, JS; McInnes, IB; Gossec, L; Strand, V; Pricop, L; Fox, T; Jugl, S; Gaillez, C Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1322 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0766 Secukinumab provides sustained remission and low disease activity related to disease activity index for psoriatic arthritis (DAPSA): 2 year results from the future 2 study. (15th June 2017) Authors: Smolen, JS; McInnes, IB; Kvien, TK; Pricop, L; Fox, T; Rasouliyan, L; Jugl, S; Gaillez, C Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AB0772 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved low disease activity related to psoriatic arthritis disease activity score (PASDAS). (15th June 2017) Authors: Coates, LC; Kvien, TK; Nash, P; Gossec, L; Strand, V; Pricop, L; Rasouliyan, L; Ding, K; Jugl, S; Gaillez, C Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1326 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. AB0780 Secukinumab sustains individual clinical responses over time in patients with psoriatic arthritis: 2-year results from a phase 3 trial, future 2. (15th June 2017) Authors: Emery, P; McInnes, IB; Mease, PJ; Schiff, M; Pricop, L; Shen, S; Wang, Z; Gaillez, C Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1329 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SAT0462 Secukinumab provides sustained pasdas related low disease activity in psoriatic arthritis: 2 year results from the future 2 study. (15th June 2017) Authors: Coates, LC; Gladman, DD; Nash, P; Fitzgerald, O; Kavanaugh, A; Rasouliyan, L; Pricorp, L; Ding, K; Gaillez, C Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 948 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. SAT0463 Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years: long-term data from the future 1 and future 2 studies. (15th June 2017) Authors: Gossec, L; Kvien, TK; Conaghan, PG; Østergaard, M; Gladman, D; Mease, P; Rasouliyan, L; Pricop, L; Gaillez, C; Jugl, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 949 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. THU0398 Secukinumab sustains individual clinical responses over time in patients with active ankylosing spondylitis: 2-year results from a phase 3 trial, measure 2. (15th June 2017) Authors: Baraliakos, X; Schiff, M; Pavelka, K; Widmer, A; Porter, B; Gaillez, C Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 358 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗